Durata Therapeutics Inc., of Chicago, will be on hand Monday afternoon at the Anti-Infective Drugs Advisory Committee meeting to discuss the new drug application (NDA) for antibiotic dalbavancin, which is under FDA review for use in acute bacterial skin and skin structure infections caused by gram-negative microorganisms, including methicillin-resistant Staphylococcus aureus.